TOP TEN perturbations for 1552541_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552541_at
Selected probe(set): 229723_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552541_at (229723_at) across 6540 perturbations tested by GENEVESTIGATOR:

TC-71 / TC-32

Relative Expression (log2-ratio):7.0840755
Number of Samples:6 / 6
Experimental TC-71
Human primary cancer cell line derived from the humerus of a patient with Ewing sarcoma. Synonyms:TC71; GM11654 Cellosaurus code:
Control TC-32
Human primary cancer cell line derived from the unspecified origin of a patient with Ewing’s sarcoma. Synonyms:TC32 Cellosaurus code:

Crohn's disease study 10 / colorectal cancer study 13 (tvvad)

Relative Expression (log2-ratio):5.047101
Number of Samples:4 / 3
Experimental Crohn's disease study 10
Colon biopsies derived from patients with Crohn's disease.
Control colorectal cancer study 13 (tvvad)
Colon biopsies derived from patients with low grade tubulovillous/villous adenoma.

Crohn's disease study 3 (baseline; non-responder; colon) / normal colon mucosa tissue

Relative Expression (log2-ratio):5.0456944
Number of Samples:7 / 6
Experimental Crohn's disease study 3 (baseline; non-responder; colon)
Colonic mucosal biopsies derived from Crohn's disease patients who are non-responders to infliximab treatment. Biopsies were taken within a week prior to the first intravenous infusion of infliximab; the response to infliximab was assessed 4 to 6 weeks after the first infliximab treatment. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication.
Control normal colon mucosa tissue
Colonic mucosal biopsy from control subject obtained at the endoscopy for polyps screening.

ulcerative colitis study 5 (baseline; non-responder) / normal colon mucosa tissue

Relative Expression (log2-ratio):4.3454514
Number of Samples:16 / 6
Experimental ulcerative colitis study 5 (baseline; non-responder)
Colonic mucosal biopsies derived from ulcerative colitis patients who are non-responders to infliximab treatment. Biopsies were taken within a week prior to the first intravenous infusion of infliximab; the response to infliximab was assessed 4 to 6 weeks after the first infliximab treatment. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication.
Control normal colon mucosa tissue
Colonic mucosal biopsy from control subject obtained at the endoscopy for polyps screening.

Sjogren's syndrome study 2 (pSS) / Sjogren's syndrome study 2 (non-pSS)

Relative Expression (log2-ratio):4.182667
Number of Samples:7 / 14
Experimental Sjogren's syndrome study 2 (pSS)
Incisional biopsy of one parotid gland of patients who fulfilled the 2002 AECG criteria for primary Sjogren's syndrome (pSS). Patients were at least 21 years old.
Control Sjogren's syndrome study 2 (non-pSS)
Incisional biopsy of one parotid gland of patients with Sicca-syndrome who did not fulfill the 2002 AECG criteria for primary Sjogren's syndrome (non-pSS Sicca). Patients were at least 21 years old.

expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)

Relative Expression (log2-ratio):-3.8292427
Number of Samples:2 / 2
Experimental expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary.
Control expO ovary cancer study 1 (dysgerminoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.

Crohn's disease study 3 (infliximab; 5mg/kg; responder; colon) / Crohn's disease study 3 (infliximab; 5mg/kg; non-responder; colon)

Relative Expression (log2-ratio):-3.7969055
Number of Samples:11 / 7
Experimental Crohn's disease study 3 (infliximab; 5mg/kg; responder; colon)
Colonic mucosal biopsies from Crohn's disease patients who are responders to infliximab treatment, taken after the first intravenous infusion of 5 mg infliximab per kg body weight. Biopsies were taken 4 weeks after the first infliximab infusion in case of a single infusion and at 6 weeks if patients received a loading dose of infliximab at weeks 0, 2 and 6. The response to infliximab was assessed at 4 to 6 weeks after the first infliximab treatment, respectively. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication. ATC code:
Control Crohn's disease study 3 (infliximab; 5mg/kg; non-responder; colon)
Colonic mucosal biopsies from Crohn's disease patients who are non-responders to infliximab treatment, taken after the first intravenous infusion of 5 mg infliximab per kg body weight. Biopsies were taken 4 weeks after the first infliximab infusion in case of a single infusion and at 6 weeks if patients received a loading dose of infliximab at weeks 0, 2 and 6. The response was assessed at 4 to 6 weeks after the first infliximab treatment, respectively. The response to infliximab was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication. ATC code:

ulcerative colitis study 11 / colorectal cancer study 13 (tvvad)

Relative Expression (log2-ratio):3.7513933
Number of Samples:3 / 3
Experimental ulcerative colitis study 11
Colon biopsies derived from patients with ulcerative colitis.
Control colorectal cancer study 13 (tvvad)
Colon biopsies derived from patients with low grade tubulovillous/villous adenoma.

Crohn's disease study 10 / colorectal cancer study 13 (crc)

Relative Expression (log2-ratio):3.620161
Number of Samples:4 / 7
Experimental Crohn's disease study 10
Colon biopsies derived from patients with Crohn's disease.
Control colorectal cancer study 13 (crc)
Colon biopsies derived from patients with colorectal carcinoma.

renal cell carcinoma study 4 / normal kidney tissue

Relative Expression (log2-ratio):3.5752144
Number of Samples:26 / 2
Experimental renal cell carcinoma study 4
Tumor tissue samples from the kidney of patients with renal cell carcinoma (RCC).
Control normal kidney tissue
Normal fetal kidney tissue samples.